Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Study explains how the B.1.1.7 SARS-CoV-2 variant is more transmissible

New research led by Thushan I. de Silva from the University of Sheffield proposes that increases in subgenomic RNA (sgRNA) expression cause increased viral transmissibility and subsequent infection. They suggest the ORF9 protein, found in high amounts of sgRNA, could be regulating interferon responses.

4 Mar 2021

Novavax COVID-19 vaccine shows efficacy against South African SARS-CoV-2 variant

Researchers in the United States and South Africa report that the NVX-CoV2373 vaccine from Novavax has proved effective at preventing coronavirus disease (COVID-19) caused by the B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently emerged in South Africa.

4 Mar 2021

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Researchers in the United States say the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant – P.1 – that has recently emerged in Brazil shows a worrying level of resistance to neutralization by antibodies.

4 Mar 2021

Combining terpenes and cannabidiol may be highly active against human coronaviruses

A group of researchers from a well-known technology company in Israel showed a significant antiviral effect of a combination of terpenes and cannabidiol against a human coronavirus strain 229E. This exciting and first-of-its-kind report is currently available on the bioRxiv preprint server.

4 Mar 2021

Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

Researchers found a small molecule that inhibits different virus proteins and significantly reduces infection in cells. Combined with the antiviral remdesivir, its potency increases significantly, suggesting it may be a potential antiviral candidate for the treatment of COVID-19.

4 Mar 2021

Delayed detection of oral fluid anti-SARS-CoV-2 antibodies increases the time to viral clearance

A prospective observational study has revealed that the late appearance of anti-SARS-CoV-2 antibodies in oral fluid, absence of fever as an early symptom, and elevated BMI are associated with delayed clearance of viral RNA in mild to moderate COVID-19 patients.

4 Mar 2021

Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

The currently approved mRNA vaccines from Moderna and Pfizer-BioNTech help create neutralizing antibodies against the SARS-CoV-2 spike protein. Both companies designed their vaccines to be delivered in two doses. However, given the limited supply of vaccines worldwide, a new modeling study has suggested that vaccinating more people with the first dose and delaying the second could be an alternate route to achieving population immunity that could reduce mortality rates.

4 Mar 2021

Multiple COVID-19 variants of concern have reached Houston, Texas

New research by a team at Houston Methodist Hospital in the United States has modeled the aggressive genomic sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) observed in the United Kingdom to document viral community spread in Houston, Texas.

4 Mar 2021

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

A new study reports the potential of the cell surface marker, CD47, as a biomarker for hyperinflammation, a characteristic feature of severe COVID-19.

4 Mar 2021

Novel host-viral-microbiome interactions during COVID-19 may determine outcome

A new preprint on the medRxiv* server discusses how the underlying disease mechanisms are regulated such that the local or mucosal immune response is distinct from the systemic response.

4 Mar 2021

Researchers detect vaccine-induced SARS-CoV-2 antibodies in breast milk

A new paper released on the medRxiv* preprint server describes, for the first time, the detection of antibodies to the virus in human breast milk following the vaccination of lactating mothers. This could guide patients, their healthcare providers, and public health policymakers alike as to the deployment of the vaccines in pregnant and lactating mothers.

4 Mar 2021

Research looks at COVID vaccine hesitancy and refusal among the U.S. public

Vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rolled out in many countries, including the United States. As the number of coronavirus disease (COVID-19) cases continues to rise, vaccinating many people in the population is crucial. Despite campaigns to inform residents of the benefits of vaccines, many are still reluctant to get vaccinated.

4 Mar 2021

Study suggests no protection against SARS-CoV-2 infection from recent exposure to HCoVs

In the study, published on the pre-print server medRxiv*, the researchers found a slight but significantly elevated risk of SARS-CoV-2 infection in households with young children between 10 months and five years old. However, recent exposure to human coronaviruses does not reduce the risk of SARS-CoV-2 infection in households with young children.

4 Mar 2021

Study reports persistent SARS-CoV-2 with increasing viral variants in pediatric patients

New research, published on medRxiv preprint server, has reported the effect of prolonged SARS-CoV-2 infection in immunocompromised children and young adults.

4 Mar 2021

SARS-CoV-2 variants do not substantially affect CD4+ and CD8+ T cell responses, study shows

Researchers from California in the United States have conducted a study showing that important adaptive immune responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not affected by four recently emerged variants of the virus.

3 Mar 2021

Study shows lower antibody cross-reactivity after infection with the B.1.1.7 SARS-CoV-2 variant

In a recent research paper currently available on the bioRxiv* preprint server, a diverse group of researchers has examined the immunogenicity of antibodies against the variant B.1.1.7 of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) initially found in the United Kingdom – and revealed diminished recognition and neutralization of either parental strains or the South African variant.

3 Mar 2021

COVID risk to households and teachers from in person schooling

When researchers analyzed the responses of the COVID-19 Symptom Survey in the United States, they found an increased risk of COVID-19 for household members when children had in-person schooling.

3 Mar 2021

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.

3 Mar 2021

Genetic variation associated with COVID-19 outcome

Host genetics play a role in disease progression and prognosis. A paper recently uploaded to the preprint server medRxiv by Dubé et al. (1st March 2021) identifies several alleles associated with the gene natriuretic peptide receptor C (NPR3) that may impact disease severity.

3 Mar 2021

Pfizer SARS-CoV-2 vaccine effective from day 11 post 1st vaccination

New research from a team of scientists in Australia finds that the second ‘booster’ dose of the Pfizer-BioNTech vaccine did not increase vaccine efficacy against severe acute respiratory syndrome (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). The results suggest one dose of the vaccine was sufficient in providing a robust immune response 11 days after inoculation.

3 Mar 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Study explains how the B.1.1.7 SARS-CoV-2 variant is more transmissible

Novavax COVID-19 vaccine shows efficacy against South African SARS-CoV-2 variant

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Combining terpenes and cannabidiol may be highly active against human coronaviruses

Study reveals a small molecule inhibits SARS-CoV-2 infection in cells

Delayed detection of oral fluid anti-SARS-CoV-2 antibodies increases the time to viral clearance

Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

Multiple COVID-19 variants of concern have reached Houston, Texas

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

Novel host-viral-microbiome interactions during COVID-19 may determine outcome

Researchers detect vaccine-induced SARS-CoV-2 antibodies in breast milk

Research looks at COVID vaccine hesitancy and refusal among the U.S. public

Study suggests no protection against SARS-CoV-2 infection from recent exposure to HCoVs

Study reports persistent SARS-CoV-2 with increasing viral variants in pediatric patients

SARS-CoV-2 variants do not substantially affect CD4+ and CD8+ T cell responses, study shows

Study shows lower antibody cross-reactivity after infection with the B.1.1.7 SARS-CoV-2 variant

COVID risk to households and teachers from in person schooling

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Genetic variation associated with COVID-19 outcome

Pfizer SARS-CoV-2 vaccine effective from day 11 post 1st vaccination

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in